Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
Stock Summary
Top Correlated Resources
019170.KS
Top 10 Correlated ETFs
019170.KS
Top 10 Correlated Stocks
019170.KS
Financial details
Company Rating
Buy
Market Cap
1191.6B
Income
-23.35B
Revenue
195.21B
Book val./share
6709.44
Cash/share
-
Dividend
-
Dividend %
-
Employees
811
Optionable
No
Shortable
Yes
Earnings
14 Nov 2022
P/E
-45.35
Forward P/E
-
PEG
0.81
P/S
5.42
P/B
3.08
P/C
-
P/FCF
-32.44
Quick Ratio
-
Current Ratio
6.86
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-458.98
EPS next Y
-
EPS next Q
-
EPS this Y
-325%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
0.45%
Revenue Q/Q
7.74%
EPS Q/Q
-13.76%
-
-
-
-
SMA20
-18.96%
SMA50
-5.97%
SMA100
-28.26%
Inst Own
-
Inst Trans
-
ROA
-6%
ROE
-7%
ROC
-0.07%
Gross Margin
39%
Oper. Margin
-13%
Profit Margin
-12%
Payout
-
Shs Outstand
49.27M
Shs Float
34.01M
-
-
-
-
Target Price
-
52W Range
19900.0-66200.0
52W High
-68.81%
52W Low
+3.77%
RSI
23.43
Rel Volume
0.44
Avg Volume
807.24K
Volume
351.61K
Perf Week
-16.4%
Perf Month
-26.77%
Perf Quarter
-46.64%
Perf Half Y
-48.31%
-
-
-
-
Beta
1.07393
-
-
Volatility
690.61%, 2575.17%
Prev Close
-3.5%
Price
20650
Change
-3.73%
Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
| Metric | History | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 3.86K | 3.91K | 3.95K | 4.09K | 3.68K | |
| Net income per share | 18.86 | 58.43 | 110.96 | 103.5 | -225 | |
| Operating cash flow per share | 211.5 | 668.06 | 403.29 | 415.05 | -1.38K | |
| Free cash flow per share | 137.34 | 629.72 | 107.77 | 350.5 | -1.49K | |
| Cash per share | 801.92 | 1.39K | 1.38K | 3.94K | 1.8K | |
| Book value per share | 4.37K | 4.3K | 4.34K | 7.72K | 6.87K | |
| Tangible book value per share | 4.2K | 4.18K | 4.17K | 7.58K | 6.71K | |
| Share holders equity per share | 4.37K | 4.3K | 4.34K | 7.72K | 6.87K | |
| Interest debt per share | 2.44K | 2.33K | 2.31K | 97.86 | 26.86 | |
| Market cap | 427.04B | 340.19B | 336.35B | 3915.32B | 1230.44B | |
| Enterprise value | 520.18B | 410.46B | 419.47B | 3861.31B | 1203.98B | |
| P/E ratio | 471.92 | 121.33 | 63.18 | 782.63 | -106.22 | |
| Price to sales ratio | 2.31 | 1.82 | 1.77 | 19.8 | 6.5 | |
| POCF ratio | 42.08 | 10.61 | 17.38 | 195.16 | -17.32 | |
| PFCF ratio | 64.8 | 11.26 | 65.05 | 231.1 | -16.05 | |
| P/B Ratio | 2.04 | 1.65 | 1.62 | 10.49 | 3.48 | |
| PTB ratio | 2.04 | 1.65 | 1.62 | 10.49 | 3.48 | |
| EV to sales | 2.81 | 2.19 | 2.21 | 19.53 | 6.36 | |
| Enterprise value over EBITDA | 32.5 | 19.72 | 17.87 | 164.66 | 314.02 | |
| EV to operating cash flow | 51.26 | 12.81 | 21.68 | 192.47 | -16.95 | |
| EV to free cash flow | 78.94 | 13.58 | 81.12 | 227.91 | -15.71 | |
| Earnings yield | 0 | 0.01 | 0.02 | 0 | -0.01 | |
| Free cash flow yield | 0.02 | 0.09 | 0.02 | 0 | -0.06 | |
| Debt to equity | 0.05 | 0.01 | 0.04 | 0 | 0 | |
| Debt to assets | 0.46 | 0.46 | 0.45 | 0.23 | 0.1 | |
| Net debt to EBITDA | 5.82 | 3.38 | 3.54 | -2.3 | -6.9 | |
| Current ratio | 1.54 | 1.54 | 1.64 | 3.99 | 7.96 | |
| Interest coverage | 1.75 | 1.81 | 1.36 | 2.66 | -70.8 | |
| Income quality | 11.21 | 11.43 | 3.63 | 4.01 | 6.13 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | -0.45 | |
| Sales general and administrative to revenue | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | |
| Research and developement to revenue | 0.03 | 0.03 | 0.03 | 0.03 | 0.09 | |
| Intangibles to total assets | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | |
| Capex to operating cash flow | -0.35 | -0.06 | -0.73 | -0.16 | 0.08 | |
| Capex to revenue | -0.02 | -0.01 | -0.07 | -0.02 | -0.03 | |
| Capex to depreciation | -0.36 | -0.16 | -1.15 | -0.26 | -0.44 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 1.36K | 2.38K | 3.29K | 4.24K | 5.9K | |
| ROIC | 0.03 | 0.03 | 0.02 | 0.02 | -0.04 | |
| Return on tangible assets | 0 | 0.01 | 0.01 | 0.01 | -0.03 | |
| Graham Net | -2.37K | -1.76K | -1.67K | 2.12K | 1.53K | |
| Working capital | 74.74B | 78.44B | 85.24B | 249.47B | 198.68B | |
| Tangible asset value | 201.33B | 200.36B | 200.21B | 366.27B | 345.59B | |
| Net current asset value | 38.31B | 51.14B | 48.21B | 219.99B | 189.21B | |
| Invested capital | 0.54 | 0.52 | 0.51 | 0 | 0 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 16.98B | 14.98B | 13.58B | 8.79B | 10.42B | |
| Average inventory | 48.01B | 47.01B | 49.06B | 49.09B | 48.4B | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 87.62 | 69.28 | 59.07 | 26.46 | 39.36 | |
| Days of inventory on hand | 163.33 | 147.1 | 157.61 | 147.8 | 155.68 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 4.17 | 5.27 | 6.18 | 13.79 | 9.27 | |
| Inventory turnover | 2.23 | 2.48 | 2.32 | 2.47 | 2.34 | |
| ROE | 0 | 0.01 | 0.03 | 0.01 | -0.03 | |
| Capex per share | -74.16 | -38.34 | -295.53 | -64.55 | -109.06 |
Quarterly Fundamentals Overview
Last date of statement is 2022-06-30 for Q2
| Metric | History | 2021-06-30 | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 937.03 | 956.63 | 982.74 | 911.73 | 982.27 | |
| Net income per share | 7.91 | -39 | -226.29 | -104 | -89.69 | |
| Operating cash flow per share | -882.45 | -46.54 | -440.97 | -108.82 | 83.87 | |
| Free cash flow per share | -920.27 | -70.12 | -470.19 | -131.41 | 27.83 | |
| Cash per share | 2.78K | 2.66K | 1.83K | 1.64K | 0 | |
| Book value per share | 7.43K | 7.23K | 6.99K | 6.79K | 6.71K | |
| Tangible book value per share | 7.28K | 7.09K | 6.83K | 6.67K | 6.73K | |
| Share holders equity per share | 7.43K | 7.23K | 6.99K | 6.79K | 6.71K | |
| Interest debt per share | 232.64 | 29.07 | 23.57 | 30.95 | 3.75 | |
| Market cap | 4237.31B | 2893.26B | 1616.08B | 1984.42B | 1120.4B | |
| Enterprise value | 4194.27B | 2842.99B | 1589.62B | 1955.87B | 1120.4B | |
| P/E ratio | 2.72K | -366.67 | -35.3 | -93.03 | -60.9 | |
| Price to sales ratio | 91.78 | 59.79 | 32.51 | 42.45 | 22.24 | |
| POCF ratio | -97.46 | -1.23K | -72.45 | -355.63 | 260.51 | |
| PFCF ratio | -93.45 | -815.73 | -67.95 | -294.5 | 785.14 | |
| P/B Ratio | 11.57 | 7.91 | 4.57 | 5.7 | 3.26 | |
| PTB ratio | 11.57 | 7.91 | 4.57 | 5.7 | 3.26 | |
| EV to sales | 90.85 | 58.75 | 31.98 | 41.84 | 22.24 | |
| Enterprise value over EBITDA | 1.57K | 8.61K | -321.73 | -480.25 | -412.04 | |
| EV to operating cash flow | -96.47 | -1.21K | -71.27 | -350.51 | 260.51 | |
| EV to free cash flow | -92.5 | -801.56 | -66.84 | -290.26 | 785.14 | |
| Earnings yield | 0 | 0 | -0.01 | 0 | 0 | |
| Free cash flow yield | -0.01 | 0 | -0.01 | 0 | 0 | |
| Debt to equity | 0 | 0 | 0 | 0 | 0 | |
| Debt to assets | 0.14 | 0.12 | 0.1 | 0.1 | 0.11 | |
| Net debt to EBITDA | -16.14 | -152.27 | 5.35 | 7.01 | 0 | |
| Current ratio | 6.99 | 8.64 | 7.96 | 8.01 | 6.86 | |
| Interest coverage | -11.31 | -73.03 | -752.73 | -1.04K | -17.86 | |
| Income quality | -111.54 | 1.19 | 1.95 | 1.05 | -0.94 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.03 | 0.03 | 0.03 | 0.03 | 0.45 | |
| Research and developement to revenue | 0.07 | 0.12 | 0.1 | 0.11 | 0 | |
| Intangibles to total assets | 0.02 | 0.02 | 0.02 | 0.02 | 0 | |
| Capex to operating cash flow | 0.04 | 0.51 | 0.07 | 0.21 | -0.67 | |
| Capex to revenue | -0.04 | -0.02 | -0.03 | -0.02 | -0.06 | |
| Capex to depreciation | -0.59 | -0.38 | -0.44 | -0.36 | -0.87 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 1.15K | 2.52K | 5.97K | 3.99K | 3.68K | |
| ROIC | 0 | -0.01 | -0.02 | -0.02 | -0.01 | |
| Return on tangible assets | 0 | 0 | -0.03 | -0.01 | -0.01 | |
| Graham Net | 2.06K | 2.16K | 1.55K | 1.37K | -841.34 | |
| Working capital | 240.64B | 237.99B | 198.68B | 196.06B | 189.89B | |
| Tangible asset value | 358.9B | 358.69B | 345.59B | 341.83B | 0 | |
| Net current asset value | 221B | 219.9B | 189.21B | 184.73B | 179.15B | |
| Invested capital | 0.03 | 0 | 0 | 0 | 0 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 12.3B | 12.4B | 12.25B | 12.44B | 0 | |
| Average inventory | 49.84B | 49.01B | 49.13B | 50.55B | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 38.04 | 38.92 | 36.11 | 37.95 | 0 | |
| Days of inventory on hand | 153.81 | 149.59 | 142.82 | 154.19 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 2.37 | 2.31 | 2.49 | 2.37 | 0 | |
| Inventory turnover | 0.59 | 0.6 | 0.63 | 0.58 | 0 | |
| ROE | 0 | -0.01 | -0.03 | -0.02 | -0.01 | |
| Capex per share | -37.82 | -23.58 | -29.22 | -22.59 | -56.04 |
Frequently Asked Questions
What is Shin Poong Pharm.Co.,Ltd. stock symbol ?
Shin Poong Pharm.Co.,Ltd. is a US stock and trading under the symbol 019170.KS
What is Shin Poong Pharm.Co.,Ltd. stock quote today ?
Shin Poong Pharm.Co.,Ltd. stock price is $20650 today.
Is Shin Poong Pharm.Co.,Ltd. stock public?
Yes, Shin Poong Pharm.Co.,Ltd. is a publicly traded company.
Company Profile
- Volume Average 807.24K
- Market Capitalization 1191.6B
- Employee 811
- Headquarters Seoul,US
- IPO Date 2000-01-04
-
Website
https://shinpoong.co.kr 
Shin Poong Pharm.Co.,Ltd. manufactures and sells pharmaceutical products in South Korea. The company offers cephalosporin antibiotics; penicillin antibiotics; and finished products. It also provides active pharmaceutical ingredients; Pyramax, an anti-malarial drug; drugs for treating hypercholesterolemia, knee osteoarthritis and shoulder periarthritis, and surgical adhesion barrier; and over the counter products. The company also exports its products to approximately 50 countries. Shin Poong Pharm.Co.,Ltd. was founded in 1962 and is headquartered in Seoul, South Korea.
